We then turned to analyze a broad set of 672 clinically approved drugs, each of which was tested on the same four carcinoma cell lines as described above in the CMAP dataset, to identify the top drugs that upregulate or downregulate ACE2 expression (full results in Table EV1F). The gene discussed is ACE2; the disease is carcinoma.